Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
The chronic myeloproliferative disorders (MPDs) include the spectrum of clonal hematopoietic stem cell disorders whose phenotype derive from the primary cell expanded in a proliferative state. The MPDs (which include polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia (CEL), primary myelofibrosis (PMF), chronic myelomonocytic leukemia (CMML), and systemic mast cell disease (SMCD)) exclude chronic myeloid leukemia (CML) because of the pathognomic importance of the BCR-ABL translocation for the diagnosis and treatment of this disorder with imatinib mesylate. Empiric use of imatinib mesylate against the spectrum of BCR-ABL negative MPDs has had mixed results. Significant benefits were obtained when empiric use of imatinib in CEL and CMML led to significant clinical benefit and the discovery of the role of rearrangements of the platelet derived growth factor receptor -alpha (PDGFRa-FIP1L1 in CEL and SMCD) and -beta (PDGFRb through TEL-PDGFRb) for CMML). Empiric use of imatinib in PMF has been disappointing, and in PV quite modest. Although next generation Abelson kinase inhibitors such as dasatinib or nilotinib may expand the role for these agents in MPDs, targeted inhibition of the mutant kinase JAK2(V617F) is more likely to make significant therapeutic gains in the classic MPDs of PV, ET, and PMF.
Mesa
Ruben A
RA
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Blood. 2005 Apr 1;105(7):2664-70
15585653
Mayo Clin Proc. 2006 Apr;81(4):553-63
16610578
N Engl J Med. 2004 Jan 8;350(2):114-24
14711910
Lancet. 2003 Aug 16;362(9383):535-6
12932387
Am J Med. 2004 Nov 15;117(10):755-61
15541325
Nat Med. 1996 May;2(5):561-6
8616716
Histol Histopathol. 2004 Oct;19(4):1245-60
15375769
Eur J Haematol. 2001 Jan;66(1):37-42
11168506
Mayo Clin Proc. 1998 Dec;73(12):1177-84
9868417
Blood. 2002 Mar 15;99(6):2255-8
11877308
PLoS Med. 2006 Jul;3(7):e270
16834459
N Engl J Med. 2003 Mar 27;348(13):1201-14
12660384
Br J Haematol. 2005 Mar;128(5):690-7
15725091
Lancet. 2005 Mar 19-25;365(9464):1054-61
15781101
Blood. 1996 Aug 1;88(3):1013-8
8704209
Br J Cancer. 2006 Jun 19;94(12):1765-9
16721371
Nature. 2005 Apr 28;434(7037):1144-8
15793561
Br J Haematol. 2004 Nov;127(4):399-403
15521916
N Engl J Med. 1995 Apr 27;332(17):1132-6
7700286
Br J Haematol. 2005 Nov;131(3):320-8
16225651
Leuk Res. 2006 Nov;30(11):1457-60
16563504
Eur J Haematol. 1990 Jan;44(1):33-8
2307218
Blood. 2000 Nov 15;96(10):3374-80
11071630
N Engl J Med. 2002 Feb 28;346(9):645-52
11870241
Pathol Biol (Paris). 2001 Mar;49(2):148-52
11317960
Blood. 2006 Sep 1;108(5):1478-84
16627756
Haematologica. 2000 Jun;85(6):595-9
10870115
Cancer. 2003 Jun 1;97(11):2760-6
12767088
N Engl J Med. 2002 Feb 28;346(9):712-3
11870257
Cancer Cell. 2005 Apr;7(4):387-97
15837627
Blood. 1999 May 1;93(9):2831-8
10216077
Blood. 2007 Jul 1;110(1):375-9
17363731
Blood. 2003 Dec 1;102(12):3912-8
12920019
N Engl J Med. 2002 Aug 15;347(7):481-7
12181402
Blood. 1998 Jun 15;91(12):4419-26
9616134
J Natl Cancer Inst. 1960 Jul;25:85-109
14427847
Eur J Haematol. 2005 Feb;74(2):117-20
15654901
N Engl J Med. 2005 Jul 7;353(1):33-45
16000354
Br J Haematol. 2006 Jun;133(5):468-92
16681635
Blood. 2006 Nov 15;108(10):3472-6
16868251
Chest. 2001 Sep;120(3):801-8
11555513
Am J Hematol. 1999 May;61(1):10-5
10331505
Br J Haematol. 1997 Sep;98(4):1004-9
9326204
Leukemia. 2006 May;20(5):827-32
16498388
N Engl J Med. 2007 Feb 1;356(5):459-68
17267906
Blood. 2003 May 1;101(9):3391-7
12506022
Leuk Res. 2006 Aug;30(8):965-70
16406016
Blood. 2005 May 15;105(10):4115-9
15671439
Mayo Clin Proc. 2006 Feb;81(2):159-66
16471068
Blood. 2003 Jun 15;101(12):4714-6
12595304
Br J Haematol. 2002 Mar;116(3):576-81
11849213
J Biol Chem. 2007 Feb 9;282(6):3428-32
17178722
Blood. 2000 Apr 1;95(7):2226-33
10733489
Am J Med Sci. 1988 May;295(5):472-6
3376991
Br J Haematol. 2006 Nov;135(3):303-16
16956345
Lancet. 2002 May 4;359(9317):1577-8
12047970
N Engl J Med. 2001 Apr 5;344(14):1031-7
11287972
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Blood. 2005 Nov 1;106(9):3206-13
16030188
Curr Hematol Rep. 2003 May;2(3):264-70
12901349
Semin Thromb Hemost. 1997;23(4):357-63
9263352
Blood. 2002 May 15;99(10):3854-6
11986248
Leuk Res. 2007 Jun;31(6):737-40
17210175
Exp Hematol. 2005 May;33(5):523-30
15850829
Blood. 1951 Apr;6(4):372-5
14820991
Curr Opin Hematol. 1998 Sep;5(5):327-31
9776211
Br J Haematol. 2001 Jun;113(3):763-71
11380468
N Engl J Med. 2005 Apr 28;352(17):1779-90
15858187